ABSTRACT
Influenza vaccination remains our best measure to prevent epidemic and pandemic influenza. We must continue to improve vaccination rates for targeted populations. Antiviral options are currently limited to the neuraminidase inhibitors.
Footnotes
↵* Dr. Mossad is the site principal investigator for a study sponsored by Roche, manufacturer of oseltamivir.
- Copyright © 2007 The Cleveland Clinic Foundation. All Rights Reserved.
